Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
First new targeted therapy in more than a decade offers relief to patients with hives uncontrolled by antihistamines
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
Alnylam Pharmaceuticals secures FDA clearance for vutrisiran, marking a significant milestone in RNA interference therapeutics for a rare …
Novartis receives a landmark approval for iptacopan (Fabhalta®), offering new hope for patients with a rare kidney disorder.
Already a subscriber? Log in